Vanda Pharmaceuticals (NASDAQ:VNDA) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report published on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright assumed coverage on Vanda Pharmaceuticals in a research note on Thursday, October 31st. They set a “buy” rating and a $18.00 price objective on the stock.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ:VNDA opened at $4.61 on Wednesday. The company has a 50 day moving average price of $4.84 and a two-hundred day moving average price of $5.23. The company has a market capitalization of $268.81 million, a PE ratio of -16.46 and a beta of 0.76. Vanda Pharmaceuticals has a 52 week low of $3.46 and a 52 week high of $6.75.

Insider Activity

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of Vanda Pharmaceuticals stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $5.17, for a total value of $25,850.00. Following the sale, the director now owns 44,857 shares of the company’s stock, valued at $231,910.69. This trade represents a 10.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 8.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Meeder Asset Management Inc. acquired a new stake in Vanda Pharmaceuticals in the 2nd quarter valued at $39,000. ORG Wealth Partners LLC acquired a new stake in shares of Vanda Pharmaceuticals in the third quarter valued at about $40,000. China Universal Asset Management Co. Ltd. raised its holdings in Vanda Pharmaceuticals by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 4,374 shares in the last quarter. SG Americas Securities LLC acquired a new position in Vanda Pharmaceuticals during the second quarter valued at approximately $61,000. Finally, Price T Rowe Associates Inc. MD grew its stake in Vanda Pharmaceuticals by 18.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 2,425 shares in the last quarter. 88.14% of the stock is owned by institutional investors and hedge funds.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.